Table 2. Results.

	Cohort 1 1984–1986	Cohort 2 1996–1997	Cohort 2 Symptomatic	Cohort 2 Screened
Grade distribution: percentage grades 1, 2 and 3	8, 49.2 and 42.9	14.9, 48.3 and 36.8	12.2, 46.8 and 41	22.3, 53 and 24.7
		P=0.009 for vs cohort 1	P=0.2 for vs cohort 1	P<0.001 for vs cohort 2 symptomatic
ER-positive tumours	64.2%	71.5%	68.8%	78.4%
		(P=0.042)	P=0.325 for vs cohort 1	P=0.024 for vs cohort 2 symptomatic
Mean ER score	97.1	102
		(P=0.454)
Median ER score	104.2	120
	(IQR 0–190)	(IQR 0–180)
		(P=0.774)
PR-positive percentage	44.9	49.9
		(P=0.181)
Mean PR score	41.2	37.9
		(P=0.418)
Median PR score	0	8.3
	(IQR 0–80)	(IQR 0–61)
		(P=0.181)
Her-2-positive percentage	21.5%	20.6%
(P=0.170)
Mean Her-2 score	52.2	43.1
		(P=0.772)
Median Her-2 score	0	0
	(IQR 0–50)	(IQR 0–67)
		(P=0.773)
ER+/PR+ percentage	42.4	46.7
ER+/PR− percentage	21.8	24.8
ER−/PR− percentage	33.3	23.5
ER−/PR+ percentage	2.5	5
		(P=0.023)
	0.620	0.887	0.874	0.976
5-year breast cancer cumulative survival		(P<0.001)	P<0.001 for vs cohort 1	P=0.148 for vs cohort 2 symptomatic